La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Nkarta Dividendo

Dividendo criteri di controllo 0/6

Nkarta non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.0%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$1.53
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20

Nkarta GAAP EPS of -$0.61

Aug 11

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09

Nkarta: A Promising Natural Killer Cell Play

May 20

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Aug 23

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

May 10

Nkarta gets greenlight from the FDA for NKX019 cancer study

Apr 28

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jan 25

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di NKTX siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di NKTX siano aumentati.

Rendimento dei dividendi rispetto al mercato

Nkarta Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di NKTX rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (NKTX)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	2.0%
Previsione dell'analista in 3 anni (NKTX)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di NKTX rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di NKTX rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di NKTX per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché NKTX non ha segnalato alcun pagamento.

Nkarta Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta, Inc. Announces Executive Appointments

Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta, Inc. Appoints George Vratsanos as Board of Directors

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Nkarta, Inc., Annual General Meeting, Jun 13, 2024

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Nkarta, Inc. has completed a Follow-on Equity Offering in the amount of $240.10001 million.

New minor risk - Shareholder dilution

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta, Inc. has filed a Follow-on Equity Offering in the amount of $240.10001 million.

CEO, President & Director notifies of intention to sell stock

Nkarta: Possible Upside From H1 Update, If Positive

CEO, President & Director recently sold US$85k worth of stock

Price target increased by 7.7% to US$16.00

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Price target decreased by 11% to US$17.38

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New minor risk - Market cap size

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

New minor risk - Share price stability

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Insufficient new directors

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer

Price target decreased to US$30.36

Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

High number of new directors

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CEO, President & Director notifies of intention to sell stock

Nkarta GAAP EPS of -$0.61

Chief Financial & Business Officer exercised options and sold US$71k worth of stock

Nkarta, Inc. Announces Executive Changes

Price target decreased to US$43.56

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

Price target decreased to US$44.11

Nkarta, Inc. Announces Executive Changes

High number of new directors

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Nkarta, Inc., Annual General Meeting, Jun 08, 2022

Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors

Price target decreased to US$64.71

Nkarta, Inc. Presents NKX019 Trial in Progress Poster At the 2021 ASH Annual Meeting and Exposition

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Insider exercised options and sold US$118k worth of stock

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta, Inc.(NasdaqGS:NKTX) dropped from Russell 2500 Growth Index

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial & Business Officer notifies of intention to sell stock

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Nkarta gets greenlight from the FDA for NKX019 cancer study

CEO, President & Director notifies of intention to sell stock

Chief Financial & Business Officer exercised options and sold US$246k worth of stock

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New 90-day high: US$71.96

New 90-day high: US$35.74

New 90-day high: US$35.43

Nkarta Announces Treatment of First Patient in First-In-Human Clinical Trial of Engineered Nkg2d-Based Nk Cell Cancer Immunotherapy Nkx101

Nkarta Announces Presentation of Preclinical Data on NKX019

Nkarta, Inc. Announces Executive Changes

First half earnings released

Nkarta, Inc. has completed an IPO in the amount of $252 million.

Stabilità e crescita dei pagamenti